Oric Pharmaceuticals/$ORIC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Ticker
$ORIC
Sector
Primary listing
Employees
128
Headquarters
Website
ORIC Metrics
BasicAdvanced
$1.2B
-
-$1.89
1.69
-
Price and volume
Market cap
$1.2B
Beta
1.69
52-week high
$14.93
52-week low
$3.90
Average daily volume
1.6M
Financial strength
Current ratio
16.129
Quick ratio
15.652
Long term debt to equity
1.485
Total debt to equity
2.495
Profitability
EBITDA (TTM)
-148.484
Management effectiveness
Return on assets (TTM)
-27.69%
Return on equity (TTM)
-43.82%
Valuation
Price to book
3.3
Price to tangible book (TTM)
3.3
Price to free cash flow (TTM)
-7.433
Free cash flow yield (TTM)
-13.45%
Free cash flow per share (TTM)
-1.671
Growth
Earnings per share change (TTM)
7.82%
3-year earnings per share growth (CAGR)
-4.22%
What the Analysts think about ORIC
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
Bulls say / Bears say
ORIC boosted its cash reserves to $244 million through Q2 2025 financings, extending its cash runway to the second half of 2028 to back Phase 3 milestones. (Reuters)
ORIC entered a clinical supply agreement with Johnson & Johnson to evaluate ORIC-114 with subcutaneous amivantamab for first-line NSCLC with EGFR exon 20 insertion mutations, reducing risk by partnering with a major pharma. (ORIC Pharmaceuticals)
At the 2025 AACR Annual Meeting, ORIC presented preclinical data for ORIC-944 showing synergistic efficacy and longer progression-free survival when combined with AR inhibitors, supporting its best-in-class potential. (GlobeNewswire)
ORIC reported a net loss of $36.4 million in Q2 2025, with basic EPS of –$0.47, pointing to continued unprofitable operations. (Reuters)
The company's shift to prioritize clinical programs included reduced investment in discovery research, narrowing its pipeline and potentially limiting long-term innovation. (Reuters)
As a clinical-stage, pre-commercial company, ORIC reported no revenue in Q2 2025, highlighting its reliance on outside funding instead of product sales. (ChartMill)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
ORIC Financial Performance
Revenues and expenses
ORIC Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oric Pharmaceuticals stock?
Oric Pharmaceuticals (ORIC) has a market cap of $1.2B as of October 25, 2025.
What is the P/E ratio for Oric Pharmaceuticals stock?
The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of October 25, 2025.
Does Oric Pharmaceuticals stock pay dividends?
No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Oric Pharmaceuticals dividend payment date?
Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.
What is the beta indicator for Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) has a beta rating of 1.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.